Cocrystal Pharma, Inc.
Records under this name other than the patents Cocrystal Pharma, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 9 patents it holds.
Back to Cocrystal Pharma, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,415,321 | Nucleoside Derivatives for Treatment of Caliciviridae Infections, Including Norovirus Infections Formerly held In force · High confidence | In force | High confidence | |
| US 9,181,227 | Potent and Selective Inhibitors of Hepatitis C Virus Formerly held In force · High confidence | In force | High confidence | |
| US 9,926,295 | Potent and Selective Inhibitors of Hepatitis C Virus Formerly held In force · High confidence | In force | High confidence | |
| US 9,809,616 | Pyrimidine Nucleosides and Their Monophosphate Prodrugs for Treatment of Viral Infections and Cancer Formerly held In force · High confidence | In force | High confidence | |
| US 10,011,629 | Nucleoside Analogs for Treatment of the Flaviviridae Family of Viruses and Cancer Formerly held In force · High confidence | In force | High confidence | |
| US 9,932,326 | Potent and Selective Inhibitors of Hepatitis C Virus Formerly held Lapsed on the fee record Ended Apr 3, 2026 · High confidence | Lapsed on the fee record | Ended Apr 3, 2026 | High confidence |
| US 9,707,215 | Inhibitors of hepatitis C virus polymerase Lapsed on the fee record Ended Jul 18, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jul 18, 2025 | From the USPTO record |
| US 10,947,210 | Inhibitors of Hepatitis C virus polymerase Lapsed on the fee record Ended Mar 16, 2025 · From the USPTO record | Lapsed on the fee record | Ended Mar 16, 2025 | From the USPTO record |
| US 10,426,762 | Inhibitors of hepatitis C virus polymerase Lapsed on the fee record Ended Oct 1, 2023 · From the USPTO record | Lapsed on the fee record | Ended Oct 1, 2023 | From the USPTO record |
| US 8,895,531 | 2′-fluoronucleoside phosphonates as antiviral agents Lapsed on the fee record Ended Nov 25, 2022 · From the USPTO record | Lapsed on the fee record | Ended Nov 25, 2022 | From the USPTO record |